7-Fluoro-3-(4-methoxy-phenyl)-1H-isothiochromen-4-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异硫色烯
• 英文名称: 7-Fluoro-3-(4-methoxy-phenyl)-1H-isothiochromen-4-ol
• 英文别名: 7-fluoro-3-(4-methoxyphenyl)-1H-isothiochromen-4-ol
• 化学式: C₁₆H₁₃FO₂S
• 分子量: 288.342
• InChiKey: NADOBIHJAGRWSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  54.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Tricyclic compounds and uses thereof
  申请人：——

  公开号：US20020077333A1

  公开（公告）日：2002-06-20

  Substituted isoquinolines, isochromanones and isothiochromanones that inhibit the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6) and/or the enzyme cyclooxygenase-2 (COX-2) and/or interleukin-10 (IL-10). Compositions containing such compounds and methods of using such compounds for treatment and/or prevention of inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by TNF-alpha, IL-6, COX-2 and/or IL-10 are also disclosed.

  抑制促炎细胞因子肿瘤坏死因子-α（TNF-α）和/或白细胞介素-6（IL-6）和/或环氧合酶-2（COX-2）和/或白细胞介素-10（IL-10）的取代异喹啉酮、异色酮和异硫色酮。还公开了含有此类化合物的组合物和使用此类化合物治疗和/或预防炎症、炎症性疾病、免疫性疾病和 TNF-α、IL-6、COX-2 和/或 IL-10 介导的其他疾病的方法。
• TRICYCLIC COMPOUNDS AND USES THEREOF
  申请人：Calyx Therapeutics, Inc.

  公开号：EP1324994A2

  公开（公告）日：2003-07-09
• EP1324994A4
  申请人：——

  公开号：EP1324994A4

  公开（公告）日：2004-06-16
• [EN] TRICYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSES TRICYCLIQUES ET LEURS UTILISATIONS
  申请人：CALYX THERAPEUTICS INC

  公开号：WO2002030888A2

  公开（公告）日：2002-04-18

  Substituted isoquinolines, isochromanones and isothiochromanones that inhibit the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and/or interleukin-6 (IL-6) and/or the enzyme cyclooxygenase-2 (COX-2) and/or interleukin-10 (IL-10). Compositions containing such compounds and methods of using such compounds for treatment and/or prevention of inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by TNF-alpha, IL-6, COX-2 and/or IL-10 are also disclosed.